Adjuvant nivolumab + ipilimumab lacks efficacy for localized renal cell carcinoma
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrect
Updated on: December 22,2023
10
Adjuvant nivolumab + ipilimumab lacks efficacy for localized renal cell carcinoma
Disease-free survival (DFS) does not differ with adjuvant nivolumab plus ipilimumab (NIVO+IPI) compared with placebo in patients with localized renal cell carcinoma (RCC) at high risk for postnephrect
Updated on:December 22,2023
10
